Baghirov H
Current areas of scientific investigation include multi-receptor metabolic regulation studies, appetite and energy balance pathway research, glucose and insulin signaling investigations, fat oxidation and energy expenditure studies, advanced metabolic pathway analysis, and peptide-receptor interaction research
Common side effects may include: Nausea Diarrhea Vomiting Constipation Abdominal pain Headache Fatigue Dizziness Bloating, belching Hair loss (lower incidence) Rare, but serious side effects may include: Acute pancreatitis Gallbladder disease / cholelithiasis Acute kidney injury (typically secondary to dehydration from GI side effects) Hypoglycemia (rare without concomitant insulin or sulfonylurea) Serious allergic reactions / anaphylaxis Suicidal thoughts or behaviors (rare
Indianas state health program treats obesity as a medical condition
When a decision is to be made on whether someone should get started on [medication] or not, so I feel like this [study] will be very helpful concerning those discussions. We are building evidence that hopefully can be built into prediction models to help patients estimate, based on their individual circumstances, what is the most likely range of weight reduction given their persistence, BMI, sex, medication they are about to start at the time of decision-making on which GLP-1 medication to choose, or whether to choose pharmacotherapy or another modality for the treatment of obesity, Gasoyan said